Get the Stockscreener App
22.41
10.29%
-2.57
After Hours:
22.70
0.29
+1.29%
Greenwich Lifesciences Inc stock is traded at $22.41, with a volume of 263.17K.
It is down -10.29% in the last 24 hours and up +133.19% over the past month.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
See More
Previous Close:
$24.98
Open:
$24.22
24h Volume:
263.17K
Relative Volume:
0.88
Market Cap:
$310.48M
Revenue:
-
Net Income/Loss:
$-8.89M
P/E Ratio:
-32.01
EPS:
-0.7
Net Cash Flow:
$-6.48M
1W Performance:
+6.66%
1M Performance:
+133.19%
6M Performance:
+122.10%
1Y Performance:
+67.87%
1-Day Range:
$21.00
$24.97
1-Week Range:
$18.54
$25.20
52-Week Range:
$7.78
$30.82
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Name
Greenwich Lifesciences Inc
Sector
Industry
Phone
203-434-3290
Address
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Compare GLSI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
22.41 | 346.09M | 0 | -8.89M | -6.48M | -0.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Initiated | Noble Capital Markets | Outperform |
| Sep-01-21 | Initiated | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Stock (GLSI) Latest News
Will Greenwich LifeSciences Inc. stock outperform growth indexesMarket Risk Summary & Community Trade Idea Sharing - ulpravda.ru
Why Greenwich LifeSciences Inc. stock is a must watch in 2025Volume Weighted Average Price & Smart Beta Strategies That Actually Work - ulpravda.ru
How $594B in Precision Tech is Cracking the Metastatic Cancer Code - The Globe and Mail
Snehal Patel Buys Handful Of Shares In Greenwich LifeSciences - simplywall.st
Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Acquires 4,300 Shares - Defense World
Will Greenwich LifeSciences Inc. stock benefit from upcoming earnings reports2026 world cup usa national team group stage star players transition play group prediction preview - ulpravda.ru
A US$74m drop in the market cap of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) is not what insiders like to see after purchasing shares recently - simplywall.st
Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Acquires 4,300 Shares of Stock - MarketBeat
Head-To-Head Analysis: Greenwich LifeSciences (NASDAQ:GLSI) vs. Avalon GloboCare (NASDAQ:ALBT) - Defense World
Snehal Patel Purchases 2,900 Shares of Greenwich LifeSciences (NASDAQ:GLSI) Stock - Defense World
Is Lehar Footwears Limited Poised for a PostEarnings RallyVolatility Adjusted Trading & Free Exceptional Risk Adjusted Gains - earlytimes.in
Insider Buying: Snehal Patel Acquires Additional Shares of Green - GuruFocus
Patel, Greenwich Lifesciences CEO, buys $63k in GLSI stock By Investing.com - Investing.com Canada
Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Buys 2,900 Shares - MarketBeat
Patel, Greenwich Lifesciences CEO, buys $63k in GLSI stock - Investing.com
FY2025 Earnings Estimate for GLSI Issued By HC Wainwright - MarketBeat
How (GLSI) Movements Inform Risk Allocation Models - Stock Traders Daily
New milestone in breast cancer prevention claimed by Greenwich - The Pharma Letter
Greenwich LifeSciences extends insider share lock-up to Sept 2026 By Investing.com - Investing.com Nigeria
Greenwich LifeSciences stock soars after extending insider lock-up By Investing.com - Investing.com South Africa
Greenwich LifeSciences stock soars after extending insider lock-up - Investing.com India
What's Going On With Greenwich LifeSciences Stock Monday? - One News Page
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Greenwich LifeSciences Takes Flight As FLAMINGO 01 Breast Cancer Trial Progresses - Nasdaq
Why Did GLSI Stock Surge 25% Today? - Stocktwits
Greenwich LifeSciences extends lock-up of shares to September 2026 - marketscreener.com
Greenwich LifeSciences Extends Lock-Up Of Shares To September 2026 - TradingView — Track All Markets
Greenwich LifeSciences Extends Share Lock-Up to September For Directors, Officers - marketscreener.com
Greenwich LifeSciences extends insider share lock-up to Sept 2026 - Investing.com
Greenwich LifeSciences, Inc. Announces Extension of Lock-Up Period for Shares to September 30, 2026 - Quiver Quantitative
Biotech locks insiders out of selling stock for six years to back cancer trial - Stock Titan
Greenwich LifeSciences (NASDAQ:GLSI) Raised to "Hold" at Wall Street Zen - MarketBeat
Greenwich LifeSciences (NASDAQ:GLSI) Raised to “Hold” at Wall Street Zen - Defense World
What's Going On With Greenwich LifeSciences Friday? - Sahm
Greenwich LifeSciences Provides Additional Updates on FLAMINGO-01 and Corporate Strategy - Sahm
Greenwich LifeSciences provides updates on Phase III breast cancer trial By Investing.com - Investing.com Nigeria
Greenwich Life Sciences Provides Updates On Breast Cancer Study; Outlines Corporate Strategy - Nasdaq
Greenwich LifeSciences says burn rate for 2025 $7M through first three quarters - TipRanks
Greenwich LifeSciences provides updates on Phase III breast cancer trial - Investing.com
Greenwich LifeSciences Provides Updates on Phase III FLAMINGO-01 Clinical Trial and Corporate Strategy - Quiver Quantitative
Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Buys $51,742.00 in Stock - Defense World
How strong is Greenwich LifeSciences Inc. stock revenue growth2025 Retail Activity & Fast Gaining Stock Strategy Reports - bolumsonucanavari.com
(GLSI) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Aug PreEarnings: Will Greenwich LifeSciences Inc. stock maintain momentum in 2025 - Улправда
Will Greenwich LifeSciences Inc. stock maintain momentum in 2025July 2025 Sector Moves & Capital Efficiency Focused Strategies - Улправда
Noble Financial Sticks to Their Buy Rating for Greenwich LifeSciences (GLSI) - The Globe and Mail
Is Greenwich LifeSciences Inc. stock positioned well for digital economyQuarterly Earnings Report & Technical Pattern Based Signals - Улправда
Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Purchases 4,100 Shares of Stock - MarketBeat
Greenwich Lifesciences Inc Stock (GLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.80%
4.56%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):